Astaxanthin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells via inhibition of Nf-κb P65 and Wnt/B-Catenin in vitro

Marine Drugs

Volumn 13, Issue 10, 2015, Pages 6064-6081

  Li, Jingjing ^a   Dai, Weiqi ^a   Xia, Yujing ^a   Chen, Kan ^a   Li, Sainan ^a   Liu, Tong ^a   Zhang, Rong ^a,b   Wang, Jianrong ^a,b   Lu, Wenxia ^a,b   Zhou, Yuqing ^a,c   Yin, Qin ^a,c   Abudumijiti, Huerxidan ^a   Chen, Rongxia ^a   Zheng, Yuanyuan ^a   Wang, Fan ^a   Lu, Jie ^a   Zhou, Yingqun ^a   Guo, Chuanyong ^a   Long, Paul ^d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d NONE

Author keywords

Apoptosis; Astaxanthin; Hepatocellular carcinoma

Indexed keywords

ASTAXANTHIN; BETA CATENIN; DIMETHYL SULFOXIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; WNT PROTEIN; ANTINEOPLASTIC AGENT; XANTHOPHYLL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; CARCINOMA, HEPATOCELLULAR; DOSE RESPONSE; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; LIVER NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; TRANSCRIPTION FACTOR RELA; WNT PROTEINS; XANTHOPHYLLS;

EID: 84945950281     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13106064     Document Type: Article

References (54)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Merle, P.; Mornex, F. Medical therapies for hepatocellular carcinoma. Cancer Radiother. 2011, 15, 28-31.
3. Villanueva, A.; Hernandez-Gea, V.; Llovet, J.M. Medical therapies for hepatocellular carcinoma: A critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 34-42.
4. Yamakado, K.; Miyayama, S.; Hirota, S.; Mizunuma, K.; Nakamura, K.; Inaba, Y.; Yamamoto, S.; Matsuo, K.; Nishida, N.; Aramaki, T.; et al. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: Subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Jpn. J. Radiol. 2014, 32, 644-649.
5. Kim, J.K.; Kim, B.H.; Baek, S.M.; Shin, D.H.; Kim, W.J.; Jeon, Y.K.; Kim, S.S.; Kim, I.J. Incidentally detected inoperable malignant pheochromocytoma with hepatic metastasis treated by transcatheter arterial chemoembolization. Endocrinol. Metab. 2014, 29, 584-589.
6. Hilgard, P.; Hamami, M.; Fouly, A.E.; Scherag, A.; Muller, S.; Ertle, J.; Heusner, T.; Cicinnati, V.R.; Paul, A.; Bockisch, A.; et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010, 52, 1741-1749.
7. Tan, X.; Xie, P.; Liu, J.; Wu, H.; Xie, Y. Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: A pilot study. Asia Pac. J. Clin. Oncol. 2014, doi:10.1111/ajco.12272.
8. Cheng, P.; Dai, W.; Wang, F.; Lu, J.; Shen, M.; Chen, K.; Li, J.; Zhang, Y.; Wang, C.; Yang, J.; et al. Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways. Biochem. Biophys. Res. Commun. 2014, 443, 1162-1168.
9. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
10. Dai, W.; Wang, C.; Wang, F.; Wang, Y.; Shen, M.; Chen, K.; Cheng, P.; Zhang, Y.; Yang, J.; Zhu, R.; et al. Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem. Biophys. Res. Commun. 2014, 446, 541-548.
11. Dai, W.; Wang, F.; Lu, J.; Xia, Y.; He, L.; Chen, K.; Li, J.; Li, S.; Liu, T.; Zheng, Y.; et al. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. Oncotarget 2015, 6, 13703-13717.
12. Villanueva, A.; Toffanin, S.; Llovet, J.M. Linking molecular classification of hepatocellular carcinoma and personalized medicine: Preliminary steps. Curr. Opin. Oncol. 2008, 20, 444-453.
13. Dai, W.; Wang, F.; He, L.; Lin, C.; Wu, S.; Chen, P.; Zhang, Y.; Shen, M.; Wu, D.; Wang, C.; et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: Partial mediation by the transcription factor NFAT1. Mol. Carcinog. 2015, 54, 301-311.
14. Kavitha, K.; Kowshik, J.; Kishore, T.K.K.; Baba, A.B.; Nagini, S. Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim. Biophys. Acta. Gen. Subj. 2013, 1830, 4433-4444.
15. Wang, F.; He, L.; Dai, W.; Xu, Y.; Wu, D.; Lin, C.; Wu, S.; Cheng, P.; Zhang, Y.; Shen, M.; et al. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS ONE 2012, 7, e50638.
16. Wang, F.; Dai, W.; Wang, Y.; Shen, M.; Chen, K.; Cheng, P.; Zhang, Y.; Wang, C.; Li, J.; Zheng, Y.; et al. The Synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS ONE 2014, 9, e97414.
17. Ambati, R.R.; Phang, S.M.; Ravi, S.; Aswathanarayana, R.G. Astaxanthin: Sources, extraction, stability, biological activities and its commercial applications - A review. Mar. Drugs 2014, 12, 128-152.
18. Li, J.; Wang, F.; Xia, Y.; Dai, W.; Chen, K.; Li, S.; Liu, T.; Zheng, Y.; Wang, J.; Lu, W.; et al. Astaxanthin pretreatment attenuates hepatic ischemia reperfusion-induced apoptosis and autophagy via the ROS/MAPK pathway in mice. Mar. Drugs 2015, 13, 3368-3387.
19. Li, J.; Xia, Y.; Liu, T.; Wang, J.; Dai, W.; Wang, F.; Zheng, Y.; Chen, K.; Li, S.; Abudumijiti, H.; et al. Protective effects of astaxanthin on Con A-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis. PLoS ONE 2015, 10, e120440.
20. Shen, M.; Chen, K.; Lu, J.; Cheng, P.; Xu, L.; Dai, W.; Wang, F.; He, L.; Zhang, Y.; Chengfen, W.; et al. Protective effect of astaxanthin on liver fibrosis through modulation of TGF-beta1 expression and autophagy. Mediat. Inflamm. 2014, 2014, doi:10.1155/2014/954502.
21. Regnier, P.; Bastias, J.; Rodriguez-Ruiz, V.; Caballero-Casero, N.; Caballo, C.; Sicilia, D.; Fuentes, A.; Maire, M.; Crepin, M.; Letourneur, D.; et al. Astaxanthin from Haematococcus pluvialis prevents oxidative stress on human endothelial cells without toxicity. Mar. Drugs 2015, 13, 2857-2874.
22. Fassett, R.G.; Coombes, J.S. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009, 5, 333-342.
23. Zhang, L.; Wang, H. Multiple mechanisms of anti-cancer effects exerted by astaxanthin. Mar. Drugs 2015, 13, 4310-4330.
24. Chekanov, K.; Lobakova, E.; Selyakh, I.; Semenova, L.; Sidorov, R.; Solovchenko, A. Accumulation of astaxanthin by a new Haematococcus pluvialis strain BM1 from the white sea coastal rocks (Russia). Mar. Drugs 2014, 12, 4504-4520.
25. Guo, S.X.; Zhou, H.L.; Huang, C.L.; You, C.G.; Fang, Q.; Wu, P.; Wang, X.G.; Han, C.M. Astaxanthin attenuates early acute kidney injury following severe burns in rats by ameliorating oxidative stress and mitochondrial-related apoptosis. Mar. Drugs 2015, 13, 2105-2123.
26. Jyonouchi, H.; Sun, S.; Iijima, K.; Gross, M.D. Antitumor activity of astaxanthin and its mode of action. Nutr. Cancer 2000, 36, 59-65.
27. Kowshik, J.; Baba, A.B.; Giri, H.; Deepak Reddy, G.; Dixit, M.; Nagini, S. Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. PLoS ONE 2014, 9, e109114.
28. Rao, A.R.; Sindhuja, H.N.; Dharmesh, S.M.; Sankar, K.U.; Sarada, R.; Ravishankar, G.A. Effective inhibition of skin cancer, tyrosinase, and antioxidative properties by astaxanthin and astaxanthin esters from the green alga Haematococcus pluvialis. J. Agric. Food Chem. 2013, 61, 3842-3851.
29. Nakao, R.; Nelson, O.L.; Park, J.S.; Mathison, B.D.; Thompson, P.A.; Chew, B.P. Effect of dietary astaxanthin at different stages of mammary tumor initiation in BALB/c mice. Anticancer Res. 2010, 30, 2171-2175.
30. Ikeda, Y.; Tsuji, S.; Satoh, A.; Ishikura, M.; Shirasawa, T.; Shimizu, T. Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J. Neurochem. 2008, 107, 1730-1740.
31. Nagendraprabhu, P.; Sudhandiran, G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Investig. New Drugs 2011, 29, 207-224.
32. Tripathi, D.N.; Jena, G.B. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: Role of Nrf2, p53, p38 and phase-II enzymes. Mutat. Res. 2010, 696, 69-80.
33. Song, X.D.; Zhang, J.J.; Wang, M.R.; Liu, W.B.; Gu, X.B.; Lv, C.J. Astaxanthin induces mitochondria-mediated apoptosis in rat hepatocellular carcinoma CBRH-7919 cells. Biol. Pharm. Bull. 2011, 34, 839-844.
34. Song, X.; Wang, M.; Zhang, L.; Zhang, J.; Wang, X.; Liu, W.; Gu, X.; Lv, C. Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin. Toxicol. Mech. Methods 2012, 22, 679-686.
35. Zhou, Y.; Yin, X.; Ying, J.; Zhang, B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. BMC Cancer 2012, 12, 17.
36. Zhu, R.; Yang, J.; Xu, L.; Dai, W.; Wang, F.; Shen, M.; Zhang, Y.; Zhang, H.; Chen, K.; Cheng, P.; et al. Diagnostic performance of des-gamma-carboxy prothrombin for hepatocellular carcinoma: A meta-analysis. Gastroenterol. Res. Pract. 2014, doi:10.1155/2014/529314
37. Georgakilas, A.G.; Redon, C.E.; Ferguson, N.F.; Kryston, T.B.; Parekh, P.; Dickey, J.S.; Nakamura, A.J.; Mitchell, J.B.; Bonner, W.M.; Martin, O.A. Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol. Cancer Lett. 2014, 353, 248-257.
38. Liao, N.; Chen, S.; Ye, X.; Zhong, J.; Wu, N.; Dong, S.; Yang, B.; Liu, D. Antioxidant and anti-tumor activity of a polysaccharide from freshwater clam, Corbicula fluminea. Food Funct. 2013, 4, 539-548.
39. Selvam, T.N.; Venkatakrishnan, V.; Damodar, K.S.; Elumalai, P. Antioxidant and tumor cell suppression potential of premna serratifolia linn leaf. Toxicol. Int. 2012, 19, 31-34.
40. Maga, G.; Hubscher, U. Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J. Cell Sci. 2003, 116, 3051-3060.
41. Sebastian, C. Tracking down the origin of cancer: Metabolic reprogramming as a driver of stemness and tumorigenesis. Crit. Rev. Oncog. 2014, 19, 363-382.
42. Lindsay, J.; Esposti, M.D.; Gilmore, A.P. Bcl-2 proteins and mitochondria - Specificity in membrane targeting for death. Biochim. Biophys. Acta 2011, 1813, 532-539.
43. Farhana, L.; Dawson, M.I.; Fontana, J.A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res. 2005, 65, 4909-4917.
44. Greenspan, E.J.; Madigan, J.P.; Boardman, L.A.; Rosenberg, D.W. Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev. Res. 2011, 4, 161-171.
45. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
46. Chaturvedi, M.M.; Sung, B.; Yadav, V.R.; Kannappan, R.; Aggarwal, B.B. NF-kappaB addiction and its role in cancer: "One size does not fit all". Oncogene 2011, 30, 1615-1630.
47. Jamieson, C.; Sharma, M.; Henderson, B.R. Wnt signaling from membrane to nucleus: Beta-catenin caught in a loop. Int. J. Biochem. Cell Biol. 2012, 44, 847-850.
48. Qiao, L.; Zhang, H.; Yu, J.; Francisco, R.; Dent, P.; Ebert, M.P.; Rocken, C.; Farrell, G. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: Evidence of a cytoprotective role. Hum. Gene Ther. 2006, 17, 280-290.
49. Wang, Q.; Liu, S.; Tang, Y.; Liu, Q.; Yao, Y. MPT64 protein from Mycobacterium tuberculosis inhibits apoptosis of macrophages through NF-kB-miRNA21-Bcl-2 pathway. PLoS ONE 2014, 9, e100949.
50. Kikuchi, A.; Yamamoto, H.; Sato, A.; Matsumoto, S. New insights into the mechanism of Wnt signaling pathway activation. Int. Rev. Cell Mol. Biol. 2011, 291, 21-71.
51. Anitha, P.; Priyadarsini, R.V.; Kavitha, K.; Thiyagarajan, P.; Nagini, S. Ellagic acid coordinately attenuates Wnt/beta-catenin and NF-kappaB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis. Eur. J. Nutr. 2013, 52, 75-84.
52. Suarez, M.I.; Uribe, D.; Jaramillo, C.M.; Osorio, G.; Perez, J.C.; Lopez, R.; Hoyos, S.; Hainaut, P.; Pineau, P.; Navas, M.C. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia. Ann. Hepatol. 2015, 14, 64-74.
53. Yothaisong, S.; Thanee, M.; Namwat, N.; Yongvanit, P.; Boonmars, T.; Puapairoj, A.; Loilome, W. Opisthorchis viverrini Infection Activates the PI3K/ AKT/PTEN and Wnt/beta-catenin Signaling Pathways in a Cholangiocarcinogenesis Model. Asian Pac. J. Cancer Prev. 2014, 15, 10463-10468.
54. Mishra, R. Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Mol. Cancer 2010, 9, 144, doi:10.1186/1476-4598-9-144.